During the past decade, Owsley Brown Frazier Cancer Center conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 1 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Owsley Brown Frazier Cancer Center" are "Metastatic Pancreatic Cancer" (2 trials), "Lymphoma, B-Cell" (1 trials) and "Pancreatic Cancer" (1 trials). Many other conditions were trialed in "Owsley Brown Frazier Cancer Center" in a lesser frequency.

Most popular intervention types in "Owsley Brown Frazier Cancer Center" are "Drug" (3 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Albumin-bound paclitaxel (ABI-007)" (1 trials), "Erlotinib" (1 trials), "Folic Acid" (1 trials), "Gemcitabine" (1 trials) and "Pralatrexate" (1 trials). Other intervention names were less common.

The vast majority of trials in "Owsley Brown Frazier Cancer Center" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Owsley Brown Frazier Cancer Center". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Owsley Brown Frazier Cancer Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Owsley Brown Frazier Cancer Center, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".